Severe Asthmatic Responses: The Impact of TSLP
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24087581 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Efthymia Theofani und 3 weiteren Autor:innen. Beteiligte Einrichtung: Cellular Immunology Laboratory, Center for Basic Research, Biomedical Research Foundation of the Academy of Athens, 11527 Athens, Greece. Hauptthemen laut MEDLINE: Asthma, Hypersensitivity. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 171 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: General Secretariat for Research and Technology, GSRT and HFRI, 3rd call for HFRI Research projects to support post-doctoral researchers.
Abstract (Originalsprache)
Asthma is a chronic inflammatory disease that affects the lower respiratory system and includes several categories of patients with varying features or phenotypes. Patients with severe asthma (SA) represent a group of asthmatics that are poorly responsive to medium-to-high doses of inhaled corticosteroids and additional controllers, thus leading in some cases to life-threatening disease exacerbations. To elaborate on SA heterogeneity, the concept of asthma endotypes has been developed, with the latter being characterized as T2-high or low, depending on the type of inflammation implicated in disease pathogenesis. As SA patients exhibit curtailed responses to standard-of-care treatment, biologic therapies are prescribed as adjunctive treatments. To date, several biologics that target specific downstream effector molecules involved in disease pathophysiology have displayed superior efficacy only in patients with T2-high, eosinophilic inflammation, suggesting that upstream mediators of the inflammatory cascade could constitute an attractive therapeutic approach for difficult-to-treat asthma. One such appealing therapeutic target is thymic stromal lymphopoietin (TSLP), an epithelial-derived cytokine with critical functions in allergic diseases, including asthma. Numerous studies in both humans and mice have provided major insights pertinent to the role of TSLP in the initiation and propagation of asthmatic responses. Undoubtedly, the magnitude of TSLP in asthma pathogenesis is highlighted by the fact that the FDA recently approved tezepelumab (Tezspire), a human monoclonal antibody that targets TSLP, for SA treatment. Nevertheless, further research focusing on the biology and mode of function of TSLP in SA will considerably advance disease management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cellular Immunology Laboratory, Center for Basic Research, Biomedical Research Foundation of the Academy of Athens, 11527 Athens, Greece.
- Host Defense and Fungal Pathogenesis Lab, School of Medicine, University of Crete, 71110 Heraklion, Greece.
- Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology, 71300 Heraklion, Greece.
- Laboratory of Immune Regulation and Tolerance, School of Medicine, University of Crete, 71110 Heraklion, Greece.
Förderung
- General Secretariat for Research and Technology
- GSRT and HFRI
- 3rd call for HFRI Research projects to support post-doctoral researchers
Zitieren
APA
Theofani, E., Tsitsopoulou, A., Morianos, I., & Semitekolou, M. (2023). Severe Asthmatic Responses: The Impact of TSLP. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24087581
Vancouver
Theofani E, Tsitsopoulou A, Morianos I, Semitekolou M. Severe Asthmatic Responses: The Impact of TSLP. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24087581
BibTeX
@article{Theofani2023,
author = {Theofani, Efthymia and Tsitsopoulou, Aikaterini and Morianos, Ioannis and Semitekolou, Maria},
title = {Severe Asthmatic Responses: The Impact of TSLP},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24087581}
}
EUVIMED